全文获取类型
收费全文 | 65270篇 |
免费 | 6422篇 |
国内免费 | 2365篇 |
专业分类
耳鼻咽喉 | 949篇 |
儿科学 | 1146篇 |
妇产科学 | 220篇 |
基础医学 | 5969篇 |
口腔科学 | 7429篇 |
临床医学 | 8685篇 |
内科学 | 4851篇 |
皮肤病学 | 209篇 |
神经病学 | 1102篇 |
特种医学 | 11642篇 |
外国民族医学 | 36篇 |
外科学 | 10648篇 |
综合类 | 10616篇 |
现状与发展 | 6篇 |
预防医学 | 2346篇 |
眼科学 | 245篇 |
药学 | 3370篇 |
25篇 | |
中国医学 | 1524篇 |
肿瘤学 | 3039篇 |
出版年
2024年 | 66篇 |
2023年 | 865篇 |
2022年 | 1206篇 |
2021年 | 2210篇 |
2020年 | 2280篇 |
2019年 | 1866篇 |
2018年 | 1756篇 |
2017年 | 1974篇 |
2016年 | 2180篇 |
2015年 | 2324篇 |
2014年 | 4214篇 |
2013年 | 4965篇 |
2012年 | 4073篇 |
2011年 | 4616篇 |
2010年 | 4085篇 |
2009年 | 3865篇 |
2008年 | 3751篇 |
2007年 | 3841篇 |
2006年 | 3555篇 |
2005年 | 3217篇 |
2004年 | 2744篇 |
2003年 | 2080篇 |
2002年 | 1677篇 |
2001年 | 1474篇 |
2000年 | 1246篇 |
1999年 | 984篇 |
1998年 | 795篇 |
1997年 | 748篇 |
1996年 | 693篇 |
1995年 | 627篇 |
1994年 | 600篇 |
1993年 | 424篇 |
1992年 | 404篇 |
1991年 | 326篇 |
1990年 | 260篇 |
1989年 | 248篇 |
1988年 | 229篇 |
1987年 | 162篇 |
1986年 | 159篇 |
1985年 | 182篇 |
1984年 | 151篇 |
1983年 | 129篇 |
1982年 | 142篇 |
1981年 | 106篇 |
1980年 | 102篇 |
1979年 | 104篇 |
1978年 | 106篇 |
1977年 | 74篇 |
1976年 | 66篇 |
1975年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
The aim of the present study was to establish survival rates, as well as crestal bone loss (CBL) of narrow diameter implants (NDI), compared to regular diameter implants (RDI). The current review followed the Enhancing the QUAlity and Transparency Of health Research guidelines and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. We searched main databases (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register) for articles addressing the focused question up to and including May 2018. Meta‐analyses were conducted for CBL and survival rates. Qualitatively, three clinical studies showed comparable CBL and survival rates between NDI and RDI at follow up. Only one study showed increased CBL around NDI compared to RDI. The overall weighted mean difference (WMD) for CBL (WMD = .06, 95% confidence interval [CI] = ‐.38‐.51, P=.76) and risk difference for survival rate (risk difference = .88, 95% CI = .22‐3.50, P=.85) were not significant between the NDI and RDI groups at follow up. NDI and RDI showed comparable CBL and survival rates. However, the findings of the present study should be interpreted with caution due to significant heterogeneity and the low number of included studies. Further randomized, controlled trials should be performed in order to obtain strong conclusions. 相似文献
45.
Nil Çomunoğlu Nuray Kepil Sergülen Dervişoğlu 《Acta orthopaedica et traumatologica turcica》2019,53(1)
Objective
The aim of this study was to define histopathological features of giant cell tumor of bone, especially accompanying fibrohistiocytic or aneurysmal bone cyst like components, in the light of our institutions experience.Methods
A total of 120 cases (64 females and 56 males; mean age: 36.2 (12–80)) with ‘GCT’ diagnosed between the years 1996–2016 were included in this retrospective analysis. Cases were evaluated according to clinical features such as age, gender, localization, recurrence, metastasis and histopathological features.Results
Tumors were localized most frequently at proximal tibia and distal femur, respectively. In 11 cases areas rich in fibrohistiocytic component and in 20 cases aneurysmal bone cyst like component were observed. In 2 cases both components were present. Twenty three cases recurred. In 1 case which was primarily located at calcaneus, tumor metastasized to lung 4 years later during follow-up.Conclusion
GCT can be confused with other tumor or tumor-like lesions involving giant cells. Secondary changes such as fibrohistiocytic or aneurysmal bone cyst-like components and coagulation necrosis were frequently seen in conventional giant cell tumor of bone. For tumors having prominent fibrohistiocytic and/or aneurysmal bone cyst-like components, in order to detect characteristic areas representing GCT, additional sampling is essential. Although secondary histopathological changes do not appear to affect clinical outcome, these features are important in differential diagnosis. Approximately one fifth of GCT cases show recurrence and sacrum and foot bones were the most frequent sites for recurrence.Level of evidence
Level IV, diagnostic study. 相似文献46.
Fahrettin Covut Divya Gupta Raisa Pinto Nina Dambrosio Najla El Jurdi Howard Meyerson Masumi Ueda Merle Kolk Richard Creger Leland Metheny Brenda W. Cooper Paolo F. Caimi Ehsan Malek Folashade Otegbeye Hillard M. Lazarus Marcos De Lima Benjamin K. Tomlinson 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(2):73-82
Introduction
Induction chemotherapy with cytarabine and an anthracycline (7+3) remains the standard of care for acute myeloid leukemia (AML).Patients and Methods
We retrospectively analyzed 183 newly diagnosed AML patients to compare the utility of rapid peripheral blast clearance (PBC), day of peripheral blast disappearance, residual blasts, and cellularity at day 14 bone marrow biopsy (D14BM) in predicting clinical response to 7+3 induction, overall survival (OS), and relapse-free survival (RFS).Results
In multivariable logistic regression analysis, day 2 PBC > 85% [P = .0016] was the only predictor of remission status, with sensitivity and specificity of 75%. Peripheral blast disappearance within 5 days after induction and < 10% cellularity in D14BM predicted superior OS and RFS in multivariate analysis. Median follow-up of patients was 28 months since diagnosis. Two-year OS and RFS for patients with ≤ 10% versus > 10% cellularity at D14BM was 60.6% [95% confidence interval (CI), 50.8%-72.2%] versus 32.5% [95% CI, 23.0%-45.8%], and 51.9% [95% CI, 41.9%-64.3%] versus 28.8% [95% CI, 19.1%-43.4%], respectively [P = .0003 for OS and .002 for RFS].Conclusion
Rapid PBC after 7+3 induction showed a significant improvement in specificity compared with D14BM, with similar sensitivity. Neither of these methods were reliably specific tools for the decision of early reinduction, despite their prognostic value. Our findings indicate that morphological cellularity in D14BM is an independent prognostic factor for OS and RFS, regardless of blast percentage, and that ≤ 10% cellularity defines D14BM hypoplasia. 相似文献47.
《European journal of surgical oncology》2020,46(6):982-990
IntroductionLung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.MethodsA review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.ResultsWe identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.ConclusionNew data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers. 相似文献
48.
49.
背景:全髋关节置换后放置引流管的目的在于引流出髋部积聚的血液,以加速患者康复。但由于术中已静脉滴入氨甲环酸,并可产生确切的减少失血的效果,术后常规放置引流管是否仍有必要?目的:探讨在全髋关节置换术中静滴氨甲环酸止血的基础上术后是否需要放置引流管。方法:选择2017年6月至2019年3月山西医科大学第二医院收治的初次单侧全髋关节置换患者132例,术中均静脉滴注氨甲环酸,其中62例全髋关节置换后放置引流管(引流组),70例全髋关节置换后不放置引流管(无引流组)。比较两组术后失血量、输血率、输血量、血红蛋白值及并发症发生情况;比较术后两组患者平均住院时间;术后随访髋关节Harris评分。试验获得山西医科大学第二医院伦理委员会批准。结果与结论:①两组术后失血量、输血率、输血量与血红蛋白值比较差异均无显著性意义(P>0.05);②引流组4例发生双下肢深静脉血栓,无引流组2例发生双下肢深静脉血栓,组间比较差异无显著性意义(P>0.05);③引流组出现了3例渗血渗液、3例感染、2例肿胀瘀斑,无引流组出现了1例渗血渗液、1例肿胀瘀斑,两组切口并发症比较差异有显著性意义(P<0.05);④引流组平均住院时间长于无引流组(P<0.05);⑤两组术后1,3,6个月的髋关节Harris评分比较差异均无显著性意义(P>0.05);⑥结果表明,全髋关节置换术中静滴止血药物氨甲环酸后无需进行引流管放置。 相似文献
50.